Evinacumab in Patients with Refractory Hypercholesterolemia

In RCT (n=272), subcutabneous evinacumab reduced LDL cholesterol by >50% at maximum dose: at week 16, differences in least-squares mean change from baseline between groups on 450mg weekly, 300mg weekly, and 300mg every 2 weeks vs. placebo were −56.0, −52.9, &−38.5% (all p<0.001).

Source:

New England Journal of Medicine